{"id":74500,"date":"2022-02-23T00:00:00","date_gmt":"2022-02-23T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2022\/02\/23\/less-toxicity-seen-with-mri-guided-sbrt-for-prostate-cancer\/"},"modified":"2022-02-25T16:12:08","modified_gmt":"2022-02-25T16:12:08","slug":"less-toxicity-seen-with-mri-guided-sbrt-for-prostate-cancer","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2022\/02\/23\/less-toxicity-seen-with-mri-guided-sbrt-for-prostate-cancer\/","title":{"rendered":"Less Toxicity Seen With MRI-Guided SBRT for Prostate Cancer"},"content":{"rendered":"<h3>\n<p>Rate of acute grade \u22652 genitourinary toxicity lower with MRI guidance versus CT guidance for SBRT in men with localized prostate cancer<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>WEDNESDAY, Feb. 23, 2022 (HealthDay News) &#8212; In men receiving treatment for localized prostate cancer, the incidence of acute grade \u00e2\u0089\u00a52 genitourinary (GU) toxicity is lower with magnetic resonance imaging (MRI)-guided versus computed tomography (CT)-guided stereotactic body radiotherapy (SBRT), according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 17 to 19 in San Francisco.<\/p>\n<p>Amar Upadhyaya Kishan, M.D., from the University of California in Los Angeles, and colleagues conducted an interim analysis of the phase 3 MIRAGE trial, which compared MRI and CT guidance among men undergoing SBRT for localized prostate cancer with a pragmatic primary end point of acute grade \u00e2\u0089\u00a52 GU toxicity. One hundred patients were eligible for evaluation (51 in the CT arm and 49 in the MRI arm).<\/p>\n<p>The researchers found that men receiving MRI-guided SBRT had a significantly reduced incidence of acute grade \u00e2\u0089\u00a52 GU toxicity (47.1 versus 22.4 percent). Men receiving MRI-guided SBRT also had a significantly reduced incidence of acute grade \u00e2\u0089\u00a52 gastrointestinal (GI) toxicity (13.7 versus 0 percent). At one month after SBRT, but not at three months after, the increase in International Prostate Symptom Score was significantly higher in men receiving CT-guided SBRT.<\/p>\n<p>&#8220;MRI-guidance offers a statistically significant reduction in acute grade GU as well as GI toxicity for prostate SBRT,&#8221; a coauthor said in a statement. &#8220;Our final results are expected later this year, but we are extremely optimistic by what we&#8217;re seeing, and hope this technology will soon begin to offer men undergoing radiotherapy for prostate cancer better outcomes.&#8221;<\/p>\n<p>Several authors disclosed financial ties to the pharmaceutical and medical device industries.<\/p>\n<p><a href=\"https:\/\/cancer.ucla.edu\/Home\/Components\/News\/News\/1810\/1631\" target=\"_blank\" rel=\"noopener\">Press Release<\/a><\/p>\n<p><a href=\"https:\/\/conferences.asco.org\/gu\/attend\" target=\"_blank\" rel=\"noopener\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2021 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rate of acute grade \u22652 genitourinary toxicity lower with MRI guidance versus CT guidance for SBRT in men with localized prostate cancer<\/p>\n","protected":false},"author":6,"featured_media":74691,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-74500","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/74500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=74500"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/74500\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/74691"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=74500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=74500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=74500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}